We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 989

Punitive damages not available under section 8 of the PM (NOC) Regulations

  • Norton Rose Fulbright LLP
  • -
  • Canada
  • -
  • November 17 2014

The Supreme Court of Canada has refused Teva’s application for leave to appeal the decision of the Federal Court of Appeal which had upheld an order

Sanofi-Aventis, et al. V. Apotex Inc., et al.

  • Bereskin & Parr LLP
  • -
  • Canada
  • -
  • November 10 2014

On October 30, the Supreme Court of Canada granted leave to appeal from the Federal Court of Appeal (FCA) decision in Apotex Inc. v. Sanofi-Aventis

Privacy & cybersecurity update, issue 3 - October, 2014

  • Jones Day
  • -
  • Australia, Brazil, Canada, Chile, China, European Union, France, Germany, Hong Kong, Ireland, Italy, Japan, Mexico, Netherlands, New Zealand, Russia, Taiwan, USA
  • -
  • October 15 2014

On August 1, the Federal Trade Commission ("FTC") issued a report on mobile shopping applications. In it, the FTC found that such apps often fail to

Court affirms utility of Gleevec patent

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • February 20 2013

"Sound prediction's introduction into Canadian law was not, as I understand it, to give a crushing hammer to those who challenge patents." Snider J

Leave to appeal to SCC granted for a section 8 damages case

  • Borden Ladner Gervais LLP
  • -
  • Canada
  • -
  • November 3 2014

The Supreme Court has granted leave in a proceeding pursuant to section 8 of the PM(NOC) Regulations. Some of the issues to be decided in this

Court of Appeal again interprets utility requirement in Celebrex FCA

  • Gowling Lafleur Henderson LLP
  • -
  • Canada
  • -
  • November 1 2014

The Federal Court of Appeal has again discussed the so-called “promise doctrine” in its October 30, 2014 decision of Apotex Inc. v. Pfizer Canada Inc

Supreme Court of Canada denies leave to non- injured plaintiffs seeking restitutionary remedies under the BPCPA and Competition Act

  • Baker & McKenzie
  • -
  • Canada
  • -
  • November 11 2014

On September 4, 2014, the Supreme Court of Canada (the “Supreme Court”) dismissed the plaintiffs’ motion for leave to appeal in a proposed class

“Gene Patent” controversy comes to Canada

  • Bereskin & Parr LLP
  • -
  • Canada, USA
  • -
  • November 4 2014

Patents related to isolated DNA corresponding to a gene, as well as methods claiming the diagnostic use of such DNA sequences are often referred to

Privacy law litigation in Ontario - from the bank to the hospital and beyond

  • Davis LLP
  • -
  • Canada
  • -
  • September 22 2014

Health information is generally regarded as among the most sensitive of personal information. Even members of the Millennial Generation, who

Federal Court upholds validity of patent for escitalopram (CIPRALEX)

  • Norton Rose Fulbright Canada LLP
  • -
  • Canada
  • -
  • March 19 2013

Apotex Inc. (“Apotex”) brought an action for impeachment seeking a declaration that Lundbeck’s Canadian Patent No. 1,339,452 (the “’452 Patent”) is